Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | TPH1 | P17752 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | CTSA | P10619 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16971 | 1.00 | NNMT (0.41) | NNMTCYP1A2CYP2C9HIF1AADORA2A | |
| SCHEMBL30916085 | 0.90 | ADORA2A (0.42) | NNMTCYP1A2ADORA2APSMB5ALDH1A1 | |
| SCHEMBL16908 | 0.80 | TP53 (0.41) | ADORA2APSMB5ALDH1A1CTSA | |
| SCHEMBL16909 | 0.80 | TP53 (0.41) | ADORA2APSMB5ALDH1A1CTSA | |
| SCHEMBL931693 | 0.78 | MAPK1 (0.46) | CYP1A2CYP2C9TGFBR1ALDH1A1MAPK1 | |
| SCHEMBL1693012 | 0.77 | PTPRA (0.50) | CYP1A2CYP2C9HIF1AALDH1A1KDM4E | |
| SCHEMBL27973844 | 0.77 | PTPRA (0.50) | CYP1A2CYP2C9HIF1AALDH1A1KDM4E | |
| SCHEMBL10467278 | 0.77 | PTPRA (0.50) | CYP1A2CYP2C9HIF1AALDH1A1KDM4E | |
| SCHEMBL3054527 | 0.77 | KMT2A (0.47) | CYP1A2ADORA2AALDH1A1KDM4E | |
| SCHEMBL27715009 | 0.77 | KMT2A (0.47) | CYP1A2ADORA2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174685-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-30 | — | — | US | disclosed |
| US-11905297-B2 | OX2R compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-02-20 | — | — | US | disclosed |
| US-20230122024-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-04-20 | — | — | US | disclosed |
| US-11479560-B2 | OX2R compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2022-10-25 | — | — | US | disclosed |
| US-11472813-B2 | OX2R compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-10-18 | — | — | US | disclosed |
| US-20210163494-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210107914-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-04-15 | — | — | US | disclosed |
| EP-3773566-A1 | OX2R COMPOUNDS | Board of Regents, The University of Texas System (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-112165940-A | OX2R compound | 德克萨斯州立大学董事会 | 2021-01-01 | — | — | CN | disclosed |
| WO-2019191327-A1 | OX2R COMPOUNDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-10-03 | — | — | WO | disclosed |
| EP-2609081-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | Amgen Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479560-B2 | OX2R compounds | HCRTR2, HCRTR1, OXTR | NNMT 3689/4885CYP1A2 772/4885CYP2C9 1329/4885 |
| US-11905297-B2 | OX2R compounds | HCRTR2, HCRTR1, OXTR | NNMT 3689/4885CYP1A2 772/4885CYP2C9 1329/4885 |
| US-20240174685-A1 | OX2R Compounds | HCRTR2, HCRTR1, OXTR | NNMT 3689/4885CYP1A2 772/4885CYP2C9 1329/4885 |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, SLC5A2 | NNMT 4537/4885CYP1A2 2281/4885CYP2C9 1986/4885 |
| US-20210107914-A1 | OX2R Compounds | HCRTR2, HCRTR1, OXTR | NNMT 3689/4885CYP1A2 772/4885CYP2C9 1329/4885 |
| US-20230122024-A1 | OX2R Compounds | HCRTR2, HCRTR1, OXTR | NNMT 3689/4885CYP1A2 772/4885CYP2C9 1329/4885 |
| US-11472813-B2 | OX2R compounds | HCRTR2, HCRTR1, OXTR | NNMT 3689/4885CYP1A2 772/4885CYP2C9 1329/4885 |
| US-20210163494-A1 | OX2R Compounds | HCRTR2, HCRTR1, OXTR | NNMT 3689/4885CYP1A2 772/4885CYP2C9 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.